
This week's U.S. healthcare scan covers a 50% rise in stand-alone Medicare drug-plan premiums, the first DNA-plasmid immunotherapy approval, AI agents booking appointments and AI models misreading drug doses, a judge's ruling on Medicaid work rules, and hospital deals in Oregon, Ohio and Virginia.
fiercehealthcare.com
fiercehealthcare.com
mobihealthnews.com
mobihealthnews.com
mobihealthnews.com
chiefhealthcareexecutive.com
chiefhealthcareexecutive.com
beckershospitalreview.com
cdc.gov
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.
| Dosing claims that were wrong (%) | 2 |
| Detected errors rated serious or potentially lethal (%) | 44 |
| Dosing questions put to the models | 8,000 |
| AI models tested | 9 |
| Adults in the single-arm trial (patients) | 32 |
| Patients with at least three prior surgeries (patients) | 26 |
| Of those, share needing no surgery in year one (%) | 27 |
| DNA plasmids delivered per dose | 2 |
| Average stand-alone monthly premium (USD) | $51.00 | +50.0%vs 2026 ($34) |
| Standard Part D deductible (USD) | $700.00 | +13.8%vs 2026 ($615) |
| Non-subsidized enrollees paying more if they do nothing (%) | 76 | |
| Stand-alone plans with a zero premium in 2027 (count) | 0 |